NMNicole Muschol

Nicole Muschol

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Nicole Muschol has a total of 208 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Epilepsy Is Part of the CNS Phenotype in Classic Infantile Pompe Disease

    by Martha Caterina Faraguna, Alexander Broomfield, Serena Gasperini, Yin-Hsiu Chien, Hui-An Chen, Nicole Maria Muschol, Hernan M. Amartino, Gaia Alessandra Kullmann, Elena Procopio, Francesca Menni, et al.

    Background and ObjectivesEnzyme replacement therapy has not only significantly improved motor outcome and survival in patients with classic infantile Pompe disease, but also revealed previously unr...

  • Open Access

    Alpha-Mannosidosis: Quantitative Oligosaccharide Biomarker Analysis in Dried Blood Spots for Diagnosis, Newborn Screening, and Treatment Monitoring

    by Dominik Badekow, Michelle Jeschik, Benjamin Dreyer, Katharina Hoff, Anja Friederike Köhn, Mona Lindschau, Anna Baghdasaryan, Anibh Martin Das, Simone Harmeling, Xinying Hong, et al.

    Background: Alpha-mannosidosis (AM) is a debilitating lysosomal storage disorder (LSD) caused by insufficient activity of alpha-mannosidase, an enzyme responsible for cleavage of alpha-linked mannose residues from N-glycan-type oligosaccharides during their degradation. As a result, specific oligosaccharides accumulate in tissues and are also detectable in body fluids. AM is a progressive multi-organ disease for which hematopoietic stem cell transplantation (HSCT) and enzyme replacement therapy (ERT) are therapeutic options, however, treatment results depend considerably on early diagnosis. Therefore, inclusion of AM into newborn screening panels would significantly contribute to improving therapeutic outcome. Methods: A rapid and fully quantitative method for the specific AM oligosaccharide biomarker Man 2 GlcNAc in dried blood spots (DBS) using ultra-performance liquid chromatography coupled to tandem-mass spectrometry was developed. DBS from 420 controls, 27 AM patients (including five newborn screening samples), and 35 patients with other LSDs were analyzed. Results: A distinct separation in biomarker concentrations was observed between unaffected individuals and untreated AM patients (0.1 – 0.8 vs 3.2 – 11.3 µmol Man 2 GlcNAc/L, p 2 GlcNAc concentrations significantly differed between untreated patients and those on ERT ( n = 17, p n = 15, p p vs 0.1 – 0.8 µmol Man 2 GlcNAc/L, p =0.0001). Conclusion: We present a simple and rapid method for quantitative analysis of the specific AM oligosaccharide biomarker Man 2 GlcNAc, which is remarkably stable compared to enzymatic assays. Thus, the method is useful for selective screening in suspected cases as well as for monitoring the response to different forms of treatment. Furthermore, Man 2 GlcNAc has the potential to serve as a useful biomarker for newborn screening offering the prospect of earlier treatment initiation, improved therapeutic outcome and higher quality of life for AM patients.

  • Open Access

    Successful treatment using asfotase alfa for delayed healing of a metatarsal stress fracture in an adolescent girl with hypophosphatasia

    by Oskar Windels, Alexander Simon, Nicole Muschol, Timur Yorgan, Florian Barvencik

    Hypophosphatasia (HPP) is a rare metabolic bone disorder that can present with a wide spectrum of skeletal and extraskeletal signs and symptoms. Biochemically, HPP is characterized by a decreased activity of the tissue nonspecific alkaline phosphatase (TNSALP) and subsequent accumulation of inorganic pyrophosphate (PPi). Fractures in patients with HPP can show delayed healing or even progress to nonunion. In pediatric patients, fractures can be particularly debilitating, as children usually engage in high levels of physical activity. The 16-year-old girl, carrying a pathogenic variant in the ALPL gene, presented 17 weeks (4 months) after the initial diagnosis of a fracture at the base of the fifth metatarsal (MT-V). The patient was still symptomatic, and magnetic resonance imaging and cone beam computed tomography (CBCT) showed no radiological signs of healing despite immobilization. Given the prolonged absence of fracture consolidation, TNSALP enzyme replacement therapy with asfotase alfa (AA) was initiated and dosed according to body weight, in line with approved pediatric regimens. Thirteen weeks after initiation of AA, CBCT demonstrated full radiological consolidation. Furthermore, bone mineral density (BMD) in the fracture gap increased by 36%, returning to the average BMD level of the MT-V. Here we present, to the best of our knowledge, the first pediatric case in which treatment with AA supported healing of a delayed union stress fracture in the context of clinically diagnosed and genetically supported HPP. Our findings support considering AA initiation in pediatric patients diagnosed with HPP who present delayed fracture healing despite standard conservative management.

  • Open Access

    Delayed diagnosis of mucopolysaccharidosis type I in a patient with spinopelvic instability, short stature, and skeletal dysplasia

    by Oskar Windels, Mona Lindschau, Felix Boschann, Ralf Oheim, Nicole Muschol

    Pathogenic variants in IDUA, encoding α-L-iduronidase (IDUA), cause the autosomal recessive lysosomal storage disorder mucopolysaccharidosis type I (MPS I). Deficiency of α-L-iduronidase leads to the accumulation of partially degraded glycosaminoglycans in various tissues, including the musculoskeletal system. Clinically, typical skeletal manifestations are dysostosis multiplex, joint contractures, and low BMD. Mucopolysaccharidosis type I represents a spectrum of disease severity. Especially in attenuated disease, establishing an accurate diagnosis and initiating disease-specific therapy, including enzyme replacement therapy (ERT) and osteological treatment, is challenging. A 33-yr-old female patient presented with a history of juvenile idiopathic arthritis, persistent spinopelvic instability, and reduced BMD. Multiple surgical attempts to stabilize the spinopelvic nonunion had failed, thus osteological co-treatment with teriparatide to promote bone healing was recommended. Despite a significant BMD increase, spinopelvic nonunion persisted. Given the combination of short stature, joint contractures, and corneal clouding, a genetic skeletal dysplasia was suspected. Exome sequencing (ES) was inconclusive, whereas short-read genome sequencing (GS) revealed the combination of a 14 kb deletion and a promotor variant in IDUA. Thus, the diagnosis of MPS I in the attenuated form was made, and ERT was initiated. This case highlights the importance of considering MPS I in patients with short stature, joint contractures, skeletal dysplasia, and low BMD. Diagnosis can be overlooked in this attenuated form, underscoring the value of genetic testing, with GS offering advantages over ES. These findings emphasize the need for early diagnosis, systematic osteological evaluation, and individualized treatment strategies in patients with skeletal dysplasia.

  • Open Access

    Exploring the long-term use of ambroxol in Gaucher disease type 2: insights from two pediatric cases

    by Charlotte Aries, Anja Köhn, Karolin Täuber, Cornelia Rudolph, Tobias Böttcher, Peter Bauer, Steffen Fischer, Nicole Muschol

    Gaucher disease 2 (GD2) is a rare and rapidly progressive neuropathic lysosomal storage disorder with an average survival of 11–19 months. To date, no approved therapy is available, but the variant-dependent pharmacological chaperone ambroxol (ABX) has emerged as a promising off-label therapy. This long-term observational study encompasses 2 GD2 patients treated with high-dose ABX from the age of 4 and 1 months, respectively, in addition to enzyme replacement therapy (ERT). Previously published data of patient 1 demonstrated a significant increase in β-glucocerebrosidase activity in ABX-treated patient fibroblasts alongside nearly age-appropriate neurocognitive and motor development after 3 years of ABX therapy. Follow-up assessments at the present age of 6.5 years continued to show normal neurocognitive development. Glucosylsphingosine (Lyso-GL1) levels in cerebrospinal fluid (CSF) remained significantly decreased compared to pre-treatment levels. In patient 2, ABX-treated fibroblasts exhibited a slight increase in β-glucocerebrosidase activity. Nevertheless, Lyso-GL1 levels in CSF showed a notable decrease compared to baseline. Neurocognitive and motor function assessments at 40 months of age indicated a moderate to severe developmental delay, yet continuous developmental progress. These interim findings contribute to the mounting evidence supporting ABX as a variant-dependent treatment for GD2 patients.


  • Open Access

    Monitoring and integrated care coordination of patients with alpha-mannosidosis: A global Delphi consensus study

    by Nathalie Guffon, Barbara K. Burton, Can Ficicioglu, Martin Magner, Mercedes Gil-Campos, Monica A. Lopez-Rodriguez, Parul Jayakar, Allan M. Lund, Galit Tal, Jose Elias Garcia-Ortiz, et al.


  • Importance of lysosomal storage diseases in rheumatology

    by Charlotte Aries, Cornelia Rudolph, Nicole Muschol

    Zusammenfassung Lysosomale Speicherkrankheiten sind eine Gruppe seltener hereditärer Stoffwechselkrankheiten. Durch einen Mangel lysosomaler Enzyme akkumulieren komplexe Substrate in den Lysosomen verschiedener Organe. Abhängig vom betroffenen Enzym resultiert dies in klinisch variablen und chronisch progredienten Multiorgankrankheiten. Die Diagnosestellung erfolgt oft mit großer zeitlicher Verzögerung. Die klinische Symptomatik kann auch den Bewegungsapparat betreffen, weshalb eine grundlegende Kenntnis über lysosomale Speicherkrankheiten in der (kinder)rheumatologischen Praxis von Relevanz ist. Exemplarisch werden hier die Mukopolysaccharidose Typ I‑S, die Mukolipidose Typ III, der Morbus Gaucher und der Morbus Fabry vorgestellt. Bei Verdacht auf eine lysosomale Speicherkrankheit ist eine Bestimmung der Enzymaktivität im Trockenblut oder in Leukozyten angezeigt, teilweise lassen sich auch krankheitsspezifische Biomarker bestimmen. Zur Diagnosesicherung wird eine molekulargenetische Untersuchung ergänzt. Für 3 der hier vorgestellten Erkrankungen stehen kausale Therapien zur Verfügung, sodass der frühzeitigen Diagnosestellung eine große Bedeutung zukommt.


  • Open Access

    CNS Manifestations in Mucolipidosis Type II—A Retrospective Analysis of Longitudinal Data on Neurocognitive Development and Neuroimaging in Eleven Patients

    by Luise Sophie Ammer, Karolin Täuber, Anna Perez, Thorsten Dohrmann, Jonas Denecke, René Santer, Ulrike Blümlein, Ann-Kathrin Ozga, Sandra Pohl, Nicole Maria Muschol

    Mucolipidosis type II (MLII), an ultra-rare lysosomal storage disorder, manifests as a fatal multi-systemic disease. Mental inhibition and progressive neurodegeneration are commonly reported disease manifestations. Nevertheless, longitudinal data on neurocognitive testing and neuroimaging lack in current literature. This study aimed to provide details on central nervous system manifestations in MLII. All MLII patients with at least one standardized developmental assessment performed between 2005 and 2022 were included by retrospective chart review. A multiple mixed linear regression model was applied. Eleven patients with a median age of 34.0 months (range 1.6–159.6) underwent 32 neurocognitive and 28 adaptive behaviour assessments as well as 14 brain magnetic resonance imagings. The scales used were mainly BSID-III (42%) and VABS-II (47%). Neurocognitive testing (per patient: mean 2.9, standard deviation (SD) 2.0) performed over 0–52.1 months (median 12.1) revealed profound impairment with a mean developmental quotient of 36.7% (SD 20.4) at last assessment. The patients showed sustained development; on average, they gained 0.28 age-equivalent score points per month (confidence interval 0.17–0.38). Apart from common (63%) cervical spinal stenosis, neuroimaging revealed unspecific, non-progressive abnormalities (i.e., mild brain atrophy, white matter lesions). In summary, MLII is associated with profound developmental impairment, but not with neurodegeneration and neurocognitive decline.


  • Open Access

    Accumulation of α-synuclein mediates podocyte injury in Fabry nephropathy

    by Fabian Braun, Ahmed Abed, Dominik Sellung, Manuel Rogg, Mathias Woidy, Oysten Eikrem, Nicola Wanner, Jessica Gambardella, Sandra D. Laufer, Fabian Haas, et al.

    Current therapies for Fabry disease are based on reversing intracellular accumulation of globotriaosylceramide (Gb3) by enzyme replacement therapy (ERT) or chaperone-mediated stabilization of the defective enzyme, thereby alleviating lysosomal dysfunction. However, their effect in the reversal of end-organ damage, like kidney injury and chronic kidney disease, remains unclear. In this study, ultrastructural analysis of serial human kidney biopsies showed that long-term use of ERT reduced Gb3 accumulation in podocytes but did not reverse podocyte injury. Then, a CRISPR/Cas9–mediated α-galactosidase knockout podocyte cell line confirmed ERT-mediated reversal of Gb3 accumulation without resolution of lysosomal dysfunction. Transcriptome-based connectivity mapping and SILAC-based quantitative proteomics identified α-synuclein (SNCA) accumulation as a key event mediating podocyte injury. Genetic and pharmacological inhibition of SNCA improved lysosomal structure and function in Fabry podocytes, exceeding the benefits of ERT. Together, this work reconceptualizes Fabry-associated cell injury beyond Gb3 accumulation, and introduces SNCA modulation as a potential intervention, especially for patients with Fabry nephropathy.


  • Real-world clinical profiles of patients with alpha-mannosidosis: Baseline evaluations from the SPARKLE registry

    by Nicole M. Muschol, Nathalie Guffon, Andrea Ballabeni, Line Borgwardt, Allan Lund, Mercedes Gil-Campos, Francesca Dona, Julia B. Hennermann